However, another explanation could be that the differences observed in the extent of glutamine utilization between HMCLs and primary CD138+ malignant plasma cells from MM patients may be based on its environmental context such as ex vivo versus in vivo artifacts assessments [19]. This evidence concerns the gene SDC1 and Miyoshi myopathy.